Filing Flows

Filing Flows › Novavax (NVAX) › Next earnings date

Novavax (NVAX) earnings: beat the estimate

Novavax (NVAX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.19 against −$0.35 (+45.1%). Revenue was $68.3M for Q3 2026, -3% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+45.1% vs estimate
Beat rate80%

The last report

Novavax reported revenue of $68.3M for the third quarter 2026 (-3% Y/Y), net loss $31.4M: Licensing, royalties, and other $42.6M, Product sales $25.7M. How it makes money → · Every quarter →

Novavax: EPS against the estimate, last 5 reportsNovavax: EPS against the estimate, last 5 reportsEstimateReported−$1.17−$1.25Nov 25−$0.49$0.11Feb 26−$0.24−$0.06May 26−$0.38−$0.32Aug 26−$0.35−$0.19Nov 26
Latest (Nov 26): Estimate −$0.35, Reported −$0.19.

Novavax's latest quarter

Novavax, Q3 2026: revenue $68.3M (-3% year over year), operating margin -45.8%, net loss $31.4M, operating cash flow −$94.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did Novavax beat earnings?

Novavax (NVAX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.19 against −$0.35 (+45.1%).

When does NVAX report earnings?

The next date is not set yet.

Does Novavax usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.